Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin Diseases AND Eczema AND Healthy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1 result(s) found for: Skin Diseases AND Eczema AND Healthy. Displaying page 1 of 1.
    EudraCT Number: 2020-001518-40 Sponsor Protocol Number: LPS16764 Start Date*: 2020-12-15
    Sponsor Name:Sanofi Aventis Recherche & Developpement
    Full Title: Open-label exploratory study to evaluate the effect of dupilumab on skin barrier function in pediatric patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-000314-15 Sponsor Protocol Number: LPS15991 Start Date*: 2021-08-17
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Open label exploratory study to evaluate the effect of dupilumab on skin barrier function in patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2024-000164-37 Sponsor Protocol Number: LPS17250 Start Date*: 2024-04-09
    Sponsor Name:Sanofi (China) Investment Co., Ltd, Shanhai Branch
    Full Title: Open-label exploratory study to evaluate the effect of dupilumab on skin barrier function in Chinese patients with moderate to severe atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2024-000402-15 Sponsor Protocol Number: LPS17244 Start Date*: 2024-09-05
    Sponsor Name:Sanofi (China) Investment Co., Ltd, Shanhai Branch
    Full Title: Open-label exploratory study to evaluate the effect of dupilumab on skin barrier function in Chinese pediatric patients with moderate-to-severe atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002223-25 Sponsor Protocol Number: NL60891.091.17 Start Date*: 2018-05-25
    Sponsor Name:Radboud University Medical Center
    Full Title: Pilot study on the effect of prophylactic versus therapeutic treatment with coal tar and vaseline lanette ointment on the skin barrier repair mechanisms in absence of a chronic inflammatory compone...
    Medical condition: Atopic dermatits
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    20.0 100000004858 10003640 Atopic dermatitis and related conditions LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003542-36 Sponsor Protocol Number: LPS16763 Start Date*: 2021-01-19
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A multi-center, exploratory study to assess dupilumab effect on pruritus neuro-mechanisms in patients with atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001528-14 Sponsor Protocol Number: 67484703ADM2001 Start Date*: 2023-04-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-67484703 in Participants with Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005900-21 Sponsor Protocol Number: 77474462ADM2003 Start Date*: 2021-12-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV doses of Bermekimab f...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022864-12 Sponsor Protocol Number: AA-10-1.01 Start Date*: 2011-04-20
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab ...
    Medical condition: Disease to be investigated: 12 patients with severe chronic urticaria (CU) with or without angioedema which continously need medical treatment As a control: 6 patients with atopy syndrome consisti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    12.1 10021247 Idiopathic urticaria LLT
    12.1 10003639 Atopic dermatitis LLT
    12.1 10031673 Other atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003689-26 Sponsor Protocol Number: CLS001-CO-PR-00;CHDR1428 Start Date*: 2015-04-16
    Sponsor Name:Cutanea Life Sciences
    Full Title: A randomized, double-blind, placebo controlled study to assess the pharmacodynamics, safety/tolerability and efficacy of omiganan in patients with mild to moderate atopic dermatitis
    Medical condition: Patients with mild to moderate atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    17.1 100000004858 10003640 Atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002587-31 Sponsor Protocol Number: 77474462ADM2001 Start Date*: 2021-05-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000376-26 Sponsor Protocol Number: ZPL521/101 Start Date*: 2016-05-09
    Sponsor Name:Ziarco Pharma Ltd
    Full Title: A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Applica...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000229-24 Sponsor Protocol Number: RD.06.SPR.201593 Start Date*: 2021-02-23
    Sponsor Name:Galderma S.A.
    Full Title: An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Moderate-to-severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003639-41 Sponsor Protocol Number: UP0089 Start Date*: 2020-11-06
    Sponsor Name:UCB Biopharma SRL
    Full Title: Phase 1/2A, randomized, placebo-controlled, single-ascending dose (Part A, participant- and investigator-blind) and repeated-dose (Part B, participant-, investigator-, and sponsor-blind) study to i...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BG (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000917-38 Sponsor Protocol Number: CBPR277X2101 Start Date*: 2011-09-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multip...
    Medical condition: Part 2: Atopic Dermatitis (AD) Part 3: Netherton Syndrome (NS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10003639 Atopic dermatitis LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001091-38 Sponsor Protocol Number: SB011/02/2013 Start Date*: 2013-12-20
    Sponsor Name:sterna biologicals GmbH & Co. KG
    Full Title: A phase IIa, single-centre, randomised, vehicle-controlled, double-blind trial for assessment of efficacy, safety and tolerability of the topical formulation SB011 containing a human GATA-3 specifi...
    Medical condition: atopic eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003501-33 Sponsor Protocol Number: DECOLAD Start Date*: 2016-12-01
    Sponsor Name:AntibioTx ApS
    Full Title: A prospective, single center, randomized, double-blind, placebo controlled study in two phases to evaluate the safety and efficacy of ATx201 as a topical antibiotic agent
    Medical condition: AntibioTx has developed a topical product (ATx201) for treatment of infected eczema and infected atopic dermatitis. These infections are predominantly caused by Staphyllococcus aureus and various s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10040788 Skin and subcutaneous tissue bacterial infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001771-36 Sponsor Protocol Number: CHDR1755 Start Date*: 2019-07-16
    Sponsor Name:Centre for Human Drug Research
    Full Title: Assessment of Neublastin-Induced Skin and Sensory Alterations and Headache in Healthy Subjects and Migraine Patients
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004860-78 Sponsor Protocol Number: P1209NY Start Date*: 2014-05-09
    Sponsor Name:G. Pohl-Boskamp GmbH & Co. KG
    Full Title: A randomised, active-controlled, observer-blind, non-inferiority study to investigate the efficacy, safety and tolerability of a local treatment with dimeticone-based pediculicides in head lice inf...
    Medical condition: Pediculosis capitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10019199 Head pediculosis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000215-31 Sponsor Protocol Number: S65796 Start Date*: 2022-05-24
    Sponsor Name:UZ Leuven
    Full Title: A monocentric academic trial comparing the diagnostic value of history taking and nasal lysine aspirin provocation test in the diagnosis of AERD in CRSwNP patients
    Medical condition: Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic RhinoSinusitis with Nasal Polyps (CRSwNP)
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004855 10075084 Aspirin-exacerbated respiratory disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 10:57:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA